# US 2026/0242800 A1 · Use of prime editing in correcting mutations in cdkl5

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242800 A1
- Document ID: US20260242800A1
- Status: Published application
- Kind: A1
- Application number: 19/665,160
- Filed: 2026-05-01
- Published: 2026-08-20
- Earliest claimed: 2023-11-03
- Assignees: The Broad Institute, Inc.; President and Fellows of Harvard College
- Applicants: The Broad Institute, Inc.; President and Fellows of Harvard College
- Inventors: David R. Liu; KeIcee Everette
- Web page: https://patentgrep.com/patent/US20260242800A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 7/045: {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/8645: {Adeno-associated virus}
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2750/14123: Virus like particles [VLP]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods of using a prime editor in combination with prime editing guide RNAs (pegRNAs) and, optionally, nicking gRNAs to carry out prime editing to directly correct mutations (i.e., c.1412delA) in the CDKL5 gene that cause CDKL5 deficiency disorder. The present disclosure also provides compositions, complexes, and systems comprising the pegRNAs, nicking gRNAs, and/or prime editors disclosed herein, as well as polynucleotides and vectors encoding the same, and cells, kits, and pharmaceutical compositions comprising the same.

## Claims

### Claim 1

A method of correcting a 1412delA mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5), or TAGCTATGCCGACT (SEQ ID NO: 6), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5), or TAGCTATGCCGACT (SEQ ID NO: 6), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5) or TAGCTATGCCGACT (SEQ ID NO: 6).

### Claim 2 (depends on 1)

The method of claim 1, wherein the pegRNA comprises the sequence of any of the pegRNAs provided in Tables 1, 2, and 4, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the pegRNAs provided in Tables 1, 2, and 4.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the pegRNA comprises a gRNA scaffold sequence of GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577).

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the pegRNA comprises a reverse transcription template (RTT) comprising the sequence of any one of SEQ ID NOs: 404-563, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to of any one of SEQ ID NOs: 404-563, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to of any one of SEQ ID NOs: 404-563.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the pegRNA comprises a primer binding site comprising the sequence TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35, TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35, TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35), TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the pegRNA comprises a 3′ structured motif of the sequence CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the pegRNA comprises a terminator sequence of TTTTTT, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTTTTT, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTTTTT.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the pegRNA comprises the structure 5′-[spacer]-[gRNA scaffold]-[RTT]-[PBS]-[3′ motif]-[terminator]-3′ or 5′-[spacer]-[gRNA scaffold]-[RTT]-[PBS]-[3′ motif]-3′.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the contacting further comprises using a nicking guide RNA (ngRNA).

### Claim 10 (depends on 9)

The method of claim 9, wherein the ngRNA comprises a spacer sequence of GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13).

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein the ngRNA comprises the sequence of any one of the ngRNAs provided in Table 3, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the ngRNAs provided in Table 3.

### Claim 12 (depends on 9, 10, 11)

The method of any one of claims 9-11, wherein the ngRNA comprises a gRNA scaffold sequence of GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578).

### Claim 13 (depends on 9, 10, 11, 12)

The method of any one of claims 9-12, wherein the ngRNA comprises a terminator sequence of TTTTTT, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTTTTT, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTTTTT.

### Claim 14 (depends on 9, 10, 11, 12, 13)

The method of any one of claims 9-13, wherein the ngRNA comprises the structure 5′-[spacer]-[gRNA scaffold]-[terminator]-3′ or 5′-[spacer]-[gRNA scaffold]-3′.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the prime editor comprises (i) a napDNAbp domain, and (ii) a polymerase domain.

### Claim 16 (depends on 15)

The method of claim 15, wherein the napDNAbp domain has a nickase activity.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the napDNAbp domain is a Cas9 protein or a variant thereof.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the napDNAbp domain is a Cas9 nickase (nCas9).

### Claim 19 (depends on 15, 16, 17, 18)

The method of any one of claims 15-18, wherein the napDNAbp domain comprises a sequence of any one of the napDNAbps provided herein, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the napDNAbps provided herein.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The method of any one of claims 15-19, wherein the polymerase domain is a reverse transcriptase domain.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The method of any one of claims 15-20, wherein the polymerase domain comprises a sequence of any one of the polymerase domains provided herein, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the polymerase domains provided herein.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the prime editor is PE2, PE3, PE4, PE5, or a variant thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the prime editor is PE4max-NRCH, or a variant thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the prime editor is a PE6 prime editor.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24)

The method of any one of claim 1-21 or 24, wherein the prime editor is PE6b-NRCH, PE6c-NRCH, or PE6d-NRCH.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the method is performed in vitro.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the method is performed in vivo.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27)

The method of any one of claim 1-25 or 27, wherein the method is performed in a subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the subject is a human.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the method is a method of treating CDKL5 deficiency disorder in the subject.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the method achieves greater than 20%, greater than 25%, greater than 30%, greater than 35%, or greater than 40% correction of the 1412delA mutation.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the method results in introduction of less than 2%, less than 3%, less than 4%, or less than 5% indel byproducts in the target DNA sequence.

### Claim 33

A prime editing guide RNA (pegRNA) comprising a spacer sequence of GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5), or TAGCTATGCCGACT (SEQ ID NO: 6), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5), or TAGCTATGCCGACT (SEQ ID NO: 6), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCCGGGAGGACTGGGGAATGG (SEQ ID NO: 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO: 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO: 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO: 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO: 5), TAGCTATGCCGACT (SEQ ID NO: 6).

### Claim 34 (depends on 33)

The pegRNA of claim 33, wherein the pegRNA comprises the sequence of any of the pegRNAs provided in Tables 1, 2, and 4 herein, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the pegRNAs provided in Tables 1, 2, and 4 herein.

### Claim 35 (depends on 33, 34)

The pegRNA of claim 33 or 34, wherein the pegRNA comprises a gRNA scaffold sequence of GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAA AAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 576) or GTTTCAGAGCTATGCTGGAAACAGCATAGCAAGTTGAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 577).

### Claim 36 (depends on 33, 34, 35)

The pegRNA of any one of claims 33-35, wherein the pegRNA comprises a reverse transcription template (RTT) comprising the sequence of any one of SEQ ID NOs: 404-563, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to of any one of SEQ ID NOs: 404-563, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to of any one of SEQ ID NOs: 404-563.

### Claim 37 (depends on 33, 34, 35, 36)

The pegRNA of any one of claims 33-36, wherein the pegRNA comprises a primer binding site comprising the sequence TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35, TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35, TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTCCCCAGT, TTCCCCAGTC (SEQ ID NO: 29), TTCCCCAGTCC (SEQ ID NO: 30), TTCCCCAGTCCT (SEQ ID NO: 31), TTCCCCAGTCCTC (SEQ ID NO: 32), TTCCCCAGTCCTCC (SEQ ID NO: 33), TTCCCCAGTCCTCCC (SEQ ID NO: 34), TAGCTATGC, TAGCTATGCC (SEQ ID NO: 35), TAGCTATGCCG (SEQ ID NO: 36), TAGCTATGCCGA (SEQ ID NO: 37), TAGCTATGCCGAC (SEQ ID NO: 38), or TAGCTATGCCGACT (SEQ ID NO: 6).

### Claim 38 (depends on 33, 34, 35, 36, 37)

The pegRNA of any one of claims 33-37, wherein the pegRNA comprises a 3′ structured motif of the sequence CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CGCGGTTCTATCTAGTTACGCGTTAAACCAACTAGAA (SEQ ID NO: 14).

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The pegRNA of any one of claims 33-38, wherein the pegRNA comprises a terminator sequence of TTTTTT, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTTTTT, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTTTTT.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The pegRNA of any one of claims 33-39, wherein the pegRNA comprises comprise the structure 5′-[spacer]-[gRNA scaffold]-[RTT]-[PBS]-[3′ motif]-[terminator]-3′ or 5′-[spacer]-[gRNA scaffold]-[RTT]-[PBS]-[3′ motif]-3′.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

A composition comprising the pegRNA of any one of claims 33-40.

### Claim 42 (depends on 41)

The composition of claim 41 further comprising a nicking guide RNA (ngRNA).

### Claim 43 (depends on 42)

The composition of claim 42, wherein the ngRNA comprises a spacer sequence of GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGGGGAATTGTGTCAAGAT (SEQ ID NO: 10), GGCCTTGGTCCTGTAGGAGG (SEQ ID NO: 11), GTTGCTCACAGACTTGGAGT (SEQ ID NO: 12), or GCTGGGGAATTGTGTGAGGAT (SEQ ID NO: 13).

### Claim 44 (depends on 42, 43)

The composition of claim 42 or 43, wherein the ngRNA comprises the sequence of any one of the ngRNAs provided in Table 3, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the ngRNAs provided in Table 3.

### Claim 45 (depends on 42, 43, 44)

The composition of any one of claims 42-44, wherein the ngRNA comprises a gRNA scaffold sequence of GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTTTAAGAGCTAAGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTT ATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 578).

### Claim 46 (depends on 42, 43, 44, 45)

The composition of any one of claims 42-45, wherein the ngRNA comprises a terminator sequence of TTTTTT, or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to TTTTTT, or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to TTTTTT.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The composition of any one of claims 42-46, wherein the ngRNA comprises the structure 5′-[spacer]-[gRNA scaffold]-[terminator]-3′.

### Claim 48 (depends on 41, 42, 43, 44, 45, 46, 47)

The composition of any one of claims 41-47 further comprising a prime editor.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the prime editor comprises (i) a napDNAbp domain, and (ii) a polymerase domain.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the napDNAbp domain has a nickase activity.

### Claim 51 (depends on 49, 50)

The composition of claim 49 or 50, wherein the napDNAbp domain is a Cas9 protein or a variant thereof.

### Claim 52 (depends on 49, 50, 51)

The composition of any one of claims 49-51, wherein the napDNAbp domain is a Cas9 nickase (nCas9).

### Claim 53 (depends on 49, 50, 51, 52)

The composition of any one of claims 49-52, wherein the napDNAbp domain comprises a sequence of any one of the napDNAbps provided herein, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the napDNAbps provided herein.

### Claim 54 (depends on 49, 50, 51, 52, 53)

The composition of any one of claims 49-53, wherein the polymerase domain is a reverse transcriptase domain.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

The composition of any one of claims 49-54, wherein the polymerase domain comprises a sequence of any one of the polymerases provided herein, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the polymerases provided herein.

### Claim 56 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any one of claims 48-55, wherein the prime editor is PE2, PE3, PE4, PE5, or a variant thereof.

### Claim 57 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The composition of any one of claims 48-56, wherein the prime editor is PE4max-NRCH, or a variant thereof.

### Claim 58 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any one of claims 48-55, wherein the prime editor is a PE6 prime editor, or a variant thereof.

### Claim 59 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 58)

The composition of any one of claim 48-55 or 58, wherein the prime editor is PE6b-NRCH, PE6c-NRCH, PE6d-NRCH, or a variant thereof.

### Claim 60 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

One or more polynucleotides encoding the pegRNA of any one of claims 33-40 and/or the ngRNA of the composition of any one of claims 41-59.

### Claim 61 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The one or more polynucleotides of claim 60, wherein the one or more polynucleotides encode the prime editor of the composition of any one of claims 48-59.

### Claim 62 (depends on 60, 61)

One or more vectors comprising the one or more polynucleotides of claim 60 or 61.

### Claim 63 (depends on 62)

The one or more vectors of claim 62, wherein the vectors are AAV vectors.

### Claim 64 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

One or more AAV particles comprising the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, or the one or more vectors of claim 62 or 63.

### Claim 65 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A virus-like particle (VLP) comprising the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, or the one or more vectors of claim 62 or 63.

### Claim 66 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A pharmaceutical composition comprising the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, the one or more vectors of claim 62 or 63, the one or more AAV particles of claim 64, or the VLP of claim 65, and a pharmaceutically acceptable excipient.

### Claim 67 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A cell comprising the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, the one or more vectors of claim 62 or 63, the one or more AAV particles of claim 64, or the VLP of claim 65.

### Claim 68 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A kit comprising the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, the one or more vectors of claim 62 or 63, the one or more AAV particles of claim 64, or the VLP of claim 65.

### Claim 69 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

Use of the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, the one or more vectors of claim 62 or 63, the one or more AAV particles of claim 64, the VLP of claim 65, or the pharmaceutical composition of claim 66 in the treatment of CDKL5 deficiency disorder.

### Claim 70 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

Use of the pegRNA of any one of claims 33-40, the composition of any one of claims 41-59, the one or more polynucleotides of claim 60 or 61, the one or more vectors of claim 62 or 63, the one or more AAV particles of claim 64, the VLP of claim 65, or the pharmaceutical composition of claim 66 in the manufacture of a medicament for the treatment of CDKL5 deficiency disorder.

### Claim 71

A system comprising a pegRNA of Table 1 or Table 2, an ngRNA of Table 3, and a prime editor.

### Claim 72 (depends on 71)

The system of claim 71, wherein the prime editor is PE6b-NRCH, PE6c-NRCH, or PE6d-NRCH.

### Claim 73

A method of correcting a 1412delA mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a reverse transcription template (RTT) of the sequence of any one of SEQ ID NOs: 404-563, or a RTT at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of any one of SEQ ID NOs: 404-563, or a RTT comprising one, two, three, four, or five mutations, insertions, or deletions relative to the sequence of any one of SEQ ID NOs: 404-563.

### Claim 74

A prime editing guide RNA (pegRNA) comprising a reverse transcription template (RTT) of the sequence of any one of SEQ ID NOs: 404-563, or a RTT at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of any one of SEQ ID NOs: 404-563, or a RTT comprising one, two, three, four, or five mutations, insertions, or deletions relative to the sequence of any one of SEQ ID NOs: 404-563.

### Claim 75

A method of correcting a c.826-1 G-to-A point mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7).

### Claim 76 (depends on 75)

The method of claim 75, wherein the pegRNA comprises the sequence GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39).

### Claim 77 (depends on 75, 76)

The method of claim 75 or 76 further comprising contacting the target DNA sequence with a nicking guide RNA.

### Claim 78 (depends on 77)

The method of claim 77, wherein the nicking guide RNA comprises the sequence GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17).

### Claim 79

A pegRNA comprising a spacer sequence of GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO: 7).

### Claim 80 (depends on 79)

The pegRNA of claim 79, wherein the pegRNA comprises the sequence GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCATTTCCTAAGAAC CTGTTGAAGTTGGACCCAGCTGACAGATACTCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 39).

### Claim 81

A nicking guide RNA comprising the sequence GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GATTTCAAACCCAGAGACTTC (SEQ ID NO: 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO: 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO: 17).

### Claim 82

A method of correcting a cluster of mutations in exon 8 of CDKL5 by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of CAGAGTACGTTGCCACCAGA, or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGA, or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGA.

### Claim 83 (depends on 82)

The method of claim 82, wherein the pegRNA comprises the sequence CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41).

### Claim 84 (depends on 82, 83)

The method of claim 82 or 83 further comprising contacting the target DNA sequence with a nicking guide RNA.

### Claim 85 (depends on 84)

The method of claim 84, wherein the nicking guide RNA comprises the sequence GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18).

### Claim 86

A pegRNA comprising a spacer sequence of CAGAGTACGTTGCCACCAGA (SEQ ID NO: 8), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGA (SEQ ID NO: 8), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGA (SEQ ID NO: 8).

### Claim 87 (depends on 86)

The pegRNA of claim 86, wherein the pegRNA comprises the sequence CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGTAAGGGCTCT AGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTTAAAC CAACTAGAATTTTTTT (SEQ ID NO: 40) or CAGAGTACGTTGCCACCAGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG CTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCACCCAAGTAAGG GCTCTAGGGAGCGACACCGGCTGGTGGCAACCGCGGTTCTATCTAGTTACGCGTT AAACCAACTAGAATTTTTTT (SEQ ID NO: 41).

### Claim 88

A nicking guide RNA comprising the sequence GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTGGAAATGTCATTCTATTTT (SEQ ID NO: 18).

### Claim 89

A method for treating CDKL5 deficiency disorder (CDD) by prime editing comprising contacting a target DNA sequence comprising a CDKL5 gene comprising a pathogenic mutation with a prime editor, or a nucleotide sequence encoding a prime editor, and a pegRNA, or a nucleotide sequence encoding a prime editor, wherein the prime editor comprises an amino acid sequence of any one of SEQ ID NOs: 355-357, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence of any one of SEQ ID NOs: 355-357.

### Claim 90 (depends on 89)

The method of claim 89, wherein the pegRNA is capable of correcting a c.1412delA mutation in the CDKL5 gene.

### Claim 91 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 89, 90)

The method of claim 89 or 90, wherein the pegRNA is a pegRNA of any one of claims 33-40.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A complex comprising a pegRNA of any one of claims 1-40 and a prime editor.
